PortalPublikationenRisk-adapted, treosulfan-based therapy with auto- and allo-S...

Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial

Standard

Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial. / Koenigsmann, M; Casper, J; Kahl, C; Basara, N; Sayer, H G; Behre, G; Theurich, S; Christopeit, M; Mohren, M; Reichle, A; Metzner, B; Ganser, A; Stadler, M; Uharek, L; Balleisen, L; Hinke, A; Hinke, R; Niederwieser, D.

in: BONE MARROW TRANSPL, Jahrgang 49, Nr. 3, 01.03.2014, S. 410-5.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Koenigsmann, M, Casper, J, Kahl, C, Basara, N, Sayer, HG, Behre, G, Theurich, S, Christopeit, M, Mohren, M, Reichle, A, Metzner, B, Ganser, A, Stadler, M, Uharek, L, Balleisen, L, Hinke, A, Hinke, R & Niederwieser, D 2014, 'Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial', BONE MARROW TRANSPL, Jg. 49, Nr. 3, S. 410-5. https://doi.org/10.1038/bmt.2013.199

APA

Koenigsmann, M., Casper, J., Kahl, C., Basara, N., Sayer, H. G., Behre, G., Theurich, S., Christopeit, M., Mohren, M., Reichle, A., Metzner, B., Ganser, A., Stadler, M., Uharek, L., Balleisen, L., Hinke, A., Hinke, R., & Niederwieser, D. (2014). Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial. BONE MARROW TRANSPL, 49(3), 410-5. https://doi.org/10.1038/bmt.2013.199

Vancouver

Koenigsmann M, Casper J, Kahl C, Basara N, Sayer HG, Behre G et al. Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial. BONE MARROW TRANSPL. 2014 Mär 1;49(3):410-5. https://doi.org/10.1038/bmt.2013.199

Bibtex

@article{8bc3d29376314614aa9b98e83361b88f,
title = "Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial",
abstract = "Since the outcome of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) is highly variable, a risk-adapted treatment approach was evaluated. After two cycles of DHAP, patients received high-dose treosulfan/etoposide/carboplatinum (TEC) and autologous stem cell rescue. After TEC, low-risk patients with late relapse (>1 year after first CR who achieved CR after DHAP received no further treatment. Patients with late relapse who achieved CR or PR only after TEC underwent a second cycle of TEC. High-risk patients with early relapse/refractory disease received treosulfan/fludarabine followed by allogeneic transplantation. Rituximab was added in patients with B-cell lymphoma (86%). At entry, 36% of all 57 patients had refractory disease, 32% early and 32% late relapse. During DHAP treatment, progression occurred in 32% of patients. Of 33 patients who received TEC, 5 received second TEC and 15 allogeneic transplantation. Main toxicity after TEC was oral mucositis (CTC grades 3 and 4 in 50% and 13%, respectively). In total, 42% patients achieved CR. Median OS was 21.4 months for all patients and 32.6 for those who underwent allogeneic transplantation. International prognostic index (IPI) at study entry was highly discriminative at predicting OS (P<0.0001). Risk-adapted, treosulfan-based therapy with auto- and allo-SCT is feasible. Long-term survival is possible with allogeneic transplantation.",
author = "M Koenigsmann and J Casper and C Kahl and N Basara and Sayer, {H G} and G Behre and S Theurich and M Christopeit and M Mohren and A Reichle and B Metzner and A Ganser and M Stadler and L Uharek and L Balleisen and A Hinke and R Hinke and D Niederwieser",
year = "2014",
month = mar,
day = "1",
doi = "10.1038/bmt.2013.199",
language = "English",
volume = "49",
pages = "410--5",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial

AU - Koenigsmann, M

AU - Casper, J

AU - Kahl, C

AU - Basara, N

AU - Sayer, H G

AU - Behre, G

AU - Theurich, S

AU - Christopeit, M

AU - Mohren, M

AU - Reichle, A

AU - Metzner, B

AU - Ganser, A

AU - Stadler, M

AU - Uharek, L

AU - Balleisen, L

AU - Hinke, A

AU - Hinke, R

AU - Niederwieser, D

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Since the outcome of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) is highly variable, a risk-adapted treatment approach was evaluated. After two cycles of DHAP, patients received high-dose treosulfan/etoposide/carboplatinum (TEC) and autologous stem cell rescue. After TEC, low-risk patients with late relapse (>1 year after first CR who achieved CR after DHAP received no further treatment. Patients with late relapse who achieved CR or PR only after TEC underwent a second cycle of TEC. High-risk patients with early relapse/refractory disease received treosulfan/fludarabine followed by allogeneic transplantation. Rituximab was added in patients with B-cell lymphoma (86%). At entry, 36% of all 57 patients had refractory disease, 32% early and 32% late relapse. During DHAP treatment, progression occurred in 32% of patients. Of 33 patients who received TEC, 5 received second TEC and 15 allogeneic transplantation. Main toxicity after TEC was oral mucositis (CTC grades 3 and 4 in 50% and 13%, respectively). In total, 42% patients achieved CR. Median OS was 21.4 months for all patients and 32.6 for those who underwent allogeneic transplantation. International prognostic index (IPI) at study entry was highly discriminative at predicting OS (P<0.0001). Risk-adapted, treosulfan-based therapy with auto- and allo-SCT is feasible. Long-term survival is possible with allogeneic transplantation.

AB - Since the outcome of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) is highly variable, a risk-adapted treatment approach was evaluated. After two cycles of DHAP, patients received high-dose treosulfan/etoposide/carboplatinum (TEC) and autologous stem cell rescue. After TEC, low-risk patients with late relapse (>1 year after first CR who achieved CR after DHAP received no further treatment. Patients with late relapse who achieved CR or PR only after TEC underwent a second cycle of TEC. High-risk patients with early relapse/refractory disease received treosulfan/fludarabine followed by allogeneic transplantation. Rituximab was added in patients with B-cell lymphoma (86%). At entry, 36% of all 57 patients had refractory disease, 32% early and 32% late relapse. During DHAP treatment, progression occurred in 32% of patients. Of 33 patients who received TEC, 5 received second TEC and 15 allogeneic transplantation. Main toxicity after TEC was oral mucositis (CTC grades 3 and 4 in 50% and 13%, respectively). In total, 42% patients achieved CR. Median OS was 21.4 months for all patients and 32.6 for those who underwent allogeneic transplantation. International prognostic index (IPI) at study entry was highly discriminative at predicting OS (P<0.0001). Risk-adapted, treosulfan-based therapy with auto- and allo-SCT is feasible. Long-term survival is possible with allogeneic transplantation.

U2 - 10.1038/bmt.2013.199

DO - 10.1038/bmt.2013.199

M3 - SCORING: Journal article

C2 - 24362366

VL - 49

SP - 410

EP - 415

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 3

ER -